Ignite Creation Date:
2025-12-24 @ 11:37 PM
Ignite Modification Date:
2025-12-25 @ 9:27 PM
Study NCT ID:
NCT04578756
Status:
COMPLETED
Last Update Posted:
2025-10-27
First Post:
2020-10-01
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D012559', 'term': 'Schizophrenia'}, {'id': 'D000067877', 'term': 'Autism Spectrum Disorder'}], 'ancestors': [{'id': 'D019967', 'term': 'Schizophrenia Spectrum and Other Psychotic Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}, {'id': 'D002659', 'term': 'Child Development Disorders, Pervasive'}, {'id': 'D065886', 'term': 'Neurodevelopmental Disorders'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 310}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2021-02-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-10', 'completionDateStruct': {'date': '2025-10-06', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-10-23', 'studyFirstSubmitDate': '2020-10-01', 'studyFirstSubmitQcDate': '2020-10-01', 'lastUpdatePostDateStruct': {'date': '2025-10-27', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2020-10-08', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-10-06', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of Participants With Treatment-emergent Adverse Events (TEAEs) in the Treatment Period', 'timeFrame': 'Baseline Day 1 to Week 59', 'description': 'An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (i.e. laboratory value), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. A TEAE is an AE that occurs or worsens after receiving study drug.'}, {'measure': 'Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters', 'timeFrame': 'Baseline Day 1 to Week 52', 'description': 'Clinical laboratory parameters included tests of hematology, chemistry, urinalysis and prolactin. The investigator assessed the results for clinical significance.'}, {'measure': 'Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Parameters', 'timeFrame': 'Baseline Day 1 to Week 59', 'description': 'Vital sign parameters included blood pressure, pulse rate, body mass index (BMI), weight, and waist circumference. The investigator assessed the results for clinical significance.'}, {'measure': 'Number of Participants With Clinically Significant Changes From Baseline in Electrocardiograms (ECG)', 'timeFrame': 'Baseline Day 1 to Week 52', 'description': 'A standard 12-lead ECG was performed. The investigator determined the clinical significance of the ECG findings using the central ECG interpretation laboratory report.'}, {'measure': 'Number of Participants With Suicidal Ideation or Suicidal Behavior as Recorded on the Columbia-Suicide Severity Rating (C-SSRS) Scale', 'timeFrame': 'Baseline Day 1 to Week 52', 'description': 'C-SSRS is a clinician-rated scale that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 "wish to be dead," and 5 "active suicidal ideation with specific plan and intent". Suicidal behavior is classified on a 5-item scale: 0 "no suicidal behavior, and 4 "actual attempt".'}, {'measure': 'Change From Baseline in Abnormal Involuntary Movement Scale (AIMS)', 'timeFrame': 'Baseline Day 1 to Week 52', 'description': "AIMS assesses abnormal involuntary movements, such as tardive dyskinesia, associated with antipsychotic drugs; it measures facial, oral, extremities, and trunk movements, as well as the participant's awareness of abnormal movements. The first 10 items are rated on a none (0) to severe (4) scale. There are an additional 2 items on dental status that are answered yes or no."}, {'measure': 'Change From Baseline in Barnes Akathisia Rating Scale (BARS)', 'timeFrame': 'Baseline Day 1 to Week 52', 'description': 'BARS is a 4-item rating scale used to assess drug-induced akathisia. The scale comprises items for rating the observable restless movements that characterize the condition, the subjective awareness of restlessness, and any distress associated with the akathisia (each on a 4-point scale from normal \\[0\\] to severe \\[3\\]). In addition, there is a global severity for akathisia rated on a 6-point scale (absent \\[0\\] to severe akathisia \\[5\\]).'}, {'measure': 'Change From Baseline in Simpson-Angus Scale (SAS)', 'timeFrame': 'Baseline Day 1 to Week 52', 'description': 'SAS is a 10-item rating scale for assessment of antipsychotic-induced parkinsonism in both clinical practice and research settings. Each item ranges from 0 (normal) to 4 (extreme symptoms). The scale consists of 1 item measuring gait (hypokinesia), 6 items measuring rigidity, and 3 items measuring glabella tap, tremor, and salivation, respectively.'}, {'measure': 'Number of Participants With Clinically Significant Changes From Baseline in Opthalmologic Parameters', 'timeFrame': 'Baseline Day 1 to Week 52', 'description': 'Ocular examination parameters included Intraocular pressure (IOP) measurement, Best-corrected visual acuity (BCVA), color fundus photography, color vision testing using Hardy Rand and Rittler (HRR) plates, and assessment of Optical coherence tomography (OCT) and cataracts. The investigator assessed the results for clinical significance.'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Schizophrenia', 'Bipolar I Disorder', 'Cariprazine', 'Autism Spectrum Disorder (ASD)'], 'conditions': ['Schizophrenia', 'Bipolar I Disorder', 'Autism Spectrum Disorder (ASD)']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'http://www.abbvieclinicaltrials.com/study/?id=3070-301-001', 'label': 'Related Info'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to evaluate the long-term safety and tolerability of cariprazine in the treatment of pediatric participants with schizophrenia, bipolar I disorder, or autism spectrum disorder (ASD) and to establish the benefit-risk profile of long-term treatment in this population.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD'], 'maximumAge': '17 Years', 'minimumAge': '5 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Participants with Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) primary diagnosis of schizophrenia or bipolar I disorder, or autism spectrum disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL) at the Screening Visit 1 (for de novo subjects, or as previously confirmed in parent study for subjects who completed Study 3112-301-001 or M21-465).\n* De novo participants must have normal physical examination findings, clinical laboratory test results, and electrocardiogram (ECG) results at Screening Visit 1. Abnormal results must not be clinically significant as determined by the investigator. Participants enrolling after completion of Study M21-465 or 3112-301-001 have had monitoring of laboratory tests, physical examinations, and ECGs at the completion visit of the parent studies.\n* Participant must have a caregiver (parent or legally authorized representative) who is willing and able to be responsible for safety monitoring of the participant, provide information about the participant's condition, oversee administration of study intervention, and accompany the participant to all study visits.\n\nExclusion Criteria:\n\n* Participants with DSM-5-TR diagnosis of major depressive disorder, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, or psychotic disorder due to another medical condition. Participants with ASD that is associated with Rett disorder, fragile-X syndrome, or childhood disintegrative disorder.\n* Prior DSM-5-TR diagnosis of intellectual disability (IQ \\< 70) for schizophrenia and bipolar I disorder participants. Prior DSM-5-TR diagnosis of profound intellectual disability (IQ \\< 25) for ASD participants.\n* Participant has a condition or is in a situation, which, in the investigator's opinion, may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study."}, 'identificationModule': {'nctId': 'NCT04578756', 'acronym': '3070 Ped OLE', 'briefTitle': 'Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder', 'organization': {'class': 'INDUSTRY', 'fullName': 'AbbVie'}, 'officialTitle': 'A 52-Week, Multicenter, Open-Label, Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Subjects With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder', 'orgStudyIdInfo': {'id': '3070-301-001'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Cariprazine Dose 1', 'description': 'Participants with Schizophrenia (age 13 to 17 years and \\< 40 kg body weight) will receive cariprazine.', 'interventionNames': ['Drug: Cariprazine Flexible Dose']}, {'type': 'EXPERIMENTAL', 'label': 'Cariprazine Dose 2', 'description': 'Participants with Schizophrenia (age 13 to 17 years and \\>= 40 kg body weight) will receive cariprazine.', 'interventionNames': ['Drug: Cariprazine Flexible Dose']}, {'type': 'EXPERIMENTAL', 'label': 'Cariprazine Dose 3', 'description': 'Participants with Bipolar I Disorder (age 10 to 12 years and \\<40 kg body weight) will receive cariprazine.', 'interventionNames': ['Drug: Cariprazine Flexible Dose']}, {'type': 'EXPERIMENTAL', 'label': 'Cariprazine Dose 4', 'description': 'Participants with Bipolar I Disorder (age 10 to 12 years and \\>= 40 kg body weight) will receive cariprazine.', 'interventionNames': ['Drug: Cariprazine Flexible Dose']}, {'type': 'EXPERIMENTAL', 'label': 'Cariprazine Dose 5', 'description': 'Participants with Bipolar I Disorder (age 13 to 17 years and \\< 40 kg body weight) will receive cariprazine.', 'interventionNames': ['Drug: Cariprazine Flexible Dose']}, {'type': 'EXPERIMENTAL', 'label': 'Cariprazine Dose 6', 'description': 'Participants with Bipolar I Disorder (age 13 to 17 years and \\>= 40 kg body weight) will receive cariprazine.', 'interventionNames': ['Drug: Cariprazine Flexible Dose']}, {'type': 'EXPERIMENTAL', 'label': 'Cariprazine Dose 7', 'description': 'Participants with Autism Spectrum Disorder ( age 5 to 9 years) will receive cariprazine.', 'interventionNames': ['Drug: Cariprazine Flexible Dose']}, {'type': 'EXPERIMENTAL', 'label': 'Cariprazine Dose 8', 'description': 'Participants with Autism Spectrum Disorder (age 10 to 12 years and \\<40 kg weight) will receive cariprazine.', 'interventionNames': ['Drug: Cariprazine Flexible Dose']}, {'type': 'EXPERIMENTAL', 'label': 'Cariprazine Dose 9', 'description': 'Participants with Autism Spectrum Disorder (age 10 to 12 years and \\>=40 kg body weight) will receive cariprazine.', 'interventionNames': ['Drug: Cariprazine Flexible Dose']}, {'type': 'EXPERIMENTAL', 'label': 'Cariprazine Dose 10', 'description': 'Participants with Autism Spectrum Disorder (age 13 to 17 years and \\<40 kg weight) will receive cariprazine.', 'interventionNames': ['Drug: Cariprazine Flexible Dose']}, {'type': 'EXPERIMENTAL', 'label': 'Cariprazine Dose 11', 'description': 'Participants with Autism Spectrum Disorder (age 13 to 17 years and \\>= 40 kg body weight) will receive cariprazine.', 'interventionNames': ['Drug: Cariprazine Flexible Dose']}], 'interventions': [{'name': 'Cariprazine Flexible Dose', 'type': 'DRUG', 'description': '1 capsule to be taken orally at approximately the same time of day (morning or evening)', 'armGroupLabels': ['Cariprazine Dose 1', 'Cariprazine Dose 10', 'Cariprazine Dose 11', 'Cariprazine Dose 2', 'Cariprazine Dose 3', 'Cariprazine Dose 4', 'Cariprazine Dose 5', 'Cariprazine Dose 6', 'Cariprazine Dose 8', 'Cariprazine Dose 9']}, {'name': 'Cariprazine Flexible Dose', 'type': 'DRUG', 'description': 'Dose solution (in milliliters) to be taken orally at approximately the same time of day (morning or evening)', 'armGroupLabels': ['Cariprazine Dose 7']}]}, 'contactsLocationsModule': {'locations': [{'zip': '36303', 'city': 'Dothan', 'state': 'Alabama', 'country': 'United States', 'facility': 'Harmonex Neuroscience Research /ID# 234938', 'geoPoint': {'lat': 31.22323, 'lon': -85.39049}}, {'zip': '72712', 'city': 'Bentonville', 'state': 'Arkansas', 'country': 'United States', 'facility': 'Pillar Clinical Research /ID# 236434', 'geoPoint': {'lat': 36.37285, 'lon': -94.20882}}, {'zip': '92805', 'city': 'Anaheim', 'state': 'California', 'country': 'United States', 'facility': 'Advanced Research Center /ID# 241903', 'geoPoint': {'lat': 33.83529, 'lon': -117.9145}}, {'zip': '90807', 'city': 'Long Beach', 'state': 'California', 'country': 'United States', 'facility': 'Duplicate_Alliance for Research - Long Beach /ID# 236261', 'geoPoint': {'lat': 33.76696, 'lon': -118.18923}}, {'zip': '92868-4203', 'city': 'Orange', 'state': 'California', 'country': 'United States', 'facility': "CHOC Children's Hospital /ID# 251019", 'geoPoint': {'lat': 33.78779, 'lon': -117.85311}}, {'zip': '92868', 'city': 'Orange', 'state': 'California', 'country': 'United States', 'facility': 'ATP Clinical Research- Orange /ID# 257095', 'geoPoint': {'lat': 33.78779, 'lon': -117.85311}}, {'zip': '91730', 'city': 'Rancho Cucamonga', 'state': 'California', 'country': 'United States', 'facility': 'Prospective Research Innovations Inc /ID# 236098', 'geoPoint': {'lat': 34.1064, 'lon': -117.59311}}, {'zip': '92103-8229', 'city': 'San Diego', 'state': 'California', 'country': 'United States', 'facility': 'University of California, San Diego Department of Psychiatry /ID# 236466', 'geoPoint': {'lat': 32.71571, 'lon': -117.16472}}, {'zip': '91786', 'city': 'Upland', 'state': 'California', 'country': 'United States', 'facility': 'Pacific Clinical Research Management Group /ID# 234377', 'geoPoint': {'lat': 34.09751, 'lon': -117.64839}}, {'zip': '33122', 'city': 'Doral', 'state': 'Florida', 'country': 'United States', 'facility': 'D&H Doral Research Center-Doral /ID# 255459', 'geoPoint': {'lat': 25.81954, 'lon': -80.35533}}, {'zip': '32607', 'city': 'Gainesville', 'state': 'Florida', 'country': 'United States', 'facility': 'Sarkis Clinical Trials /ID# 236893', 'geoPoint': {'lat': 29.65163, 'lon': -82.32483}}, {'zip': '33016', 'city': 'Hialeah', 'state': 'Florida', 'country': 'United States', 'facility': 'Galiz Research- Palmetto Medical Plaza /ID# 236277', 'geoPoint': {'lat': 25.8576, 'lon': -80.27811}}, {'zip': '33030-4613', 'city': 'Homestead', 'state': 'Florida', 'country': 'United States', 'facility': 'Advanced Research Institute of Miami /ID# 242505', 'geoPoint': {'lat': 25.46872, 'lon': -80.47756}}, {'zip': '32746', 'city': 'Lake Mary', 'state': 'Florida', 'country': 'United States', 'facility': 'Duplicate_Sandhill Research LLC /ID# 251239', 'geoPoint': {'lat': 28.75888, 'lon': -81.31784}}, {'zip': '33125', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Columbus Clinical Services, Llc /Id# 234281', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33126-2018', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'G+C Research Group, LLC /ID# 261398', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33174', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Florida Research Center, Inc. /ID# 236515', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33176-3227', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Links Clinical Trials /ID# 240975', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33166-7225', 'city': 'Miami Springs', 'state': 'Florida', 'country': 'United States', 'facility': 'South Florida Research Ph I-IV /ID# 237453', 'geoPoint': {'lat': 25.82232, 'lon': -80.2895}}, {'zip': '32751', 'city': 'Orlando', 'state': 'Florida', 'country': 'United States', 'facility': 'K2 Medical Research - Orlando - South Orlando Avenue /ID# 257528', 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'zip': '32803', 'city': 'Orlando', 'state': 'Florida', 'country': 'United States', 'facility': 'APG Research, LLC /ID# 251153', 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'zip': '33321-2979', 'city': 'Tamarac', 'state': 'Florida', 'country': 'United States', 'facility': 'D&H Tamarac Research Center /ID# 250435', 'geoPoint': {'lat': 26.21286, 'lon': -80.24977}}, {'zip': '30331', 'city': 'Atlanta', 'state': 'Georgia', 'country': 'United States', 'facility': 'Atlanta Center for Medical Research /ID# 234698', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '30030', 'city': 'Decatur', 'state': 'Georgia', 'country': 'United States', 'facility': 'CenExcel iResearch LLC /ID# 237391', 'geoPoint': {'lat': 33.77483, 'lon': -84.29631}}, {'zip': '30338', 'city': 'Dunwoody', 'state': 'Georgia', 'country': 'United States', 'facility': 'Atlanta Behavioral Research, LLC /ID# 236374', 'geoPoint': {'lat': 33.94621, 'lon': -84.33465}}, {'zip': '60169', 'city': 'Hoffman Estates', 'state': 'Illinois', 'country': 'United States', 'facility': 'Ascension Illinois /ID# 235857', 'geoPoint': {'lat': 42.04281, 'lon': -88.0798}}, {'zip': '07111', 'city': 'Irvington', 'state': 'New Jersey', 'country': 'United States', 'facility': 'Med Clinical Research Partners LLC /ID# 236071', 'geoPoint': {'lat': 40.73232, 'lon': -74.23487}}, {'zip': '14215', 'city': 'Buffalo', 'state': 'New York', 'country': 'United States', 'facility': 'Erie County Medical Center /ID# 237204', 'geoPoint': {'lat': 42.88645, 'lon': -78.87837}}, {'zip': '28501-1603', 'city': 'Kinston', 'state': 'North Carolina', 'country': 'United States', 'facility': 'New Dawn Psychiatric Services PLLC /ID# 236597', 'geoPoint': {'lat': 35.26266, 'lon': -77.58164}}, {'zip': '44012', 'city': 'Avon Lake', 'state': 'Ohio', 'country': 'United States', 'facility': 'Quest Therapeutics of Avon Lake /ID# 235956', 'geoPoint': {'lat': 41.50532, 'lon': -82.0282}}, {'zip': '45219', 'city': 'Cincinnati', 'state': 'Ohio', 'country': 'United States', 'facility': 'University of Cincinnati /ID# 236913', 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'zip': '45229', 'city': 'Cincinnati', 'state': 'Ohio', 'country': 'United States', 'facility': "Cincinnati Children's Hospital /ID# 251020", 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'zip': '45069', 'city': 'West Chester', 'state': 'Ohio', 'country': 'United States', 'facility': 'CincyScience /ID# 236390', 'geoPoint': {'lat': 39.33172, 'lon': -84.40716}}, {'zip': '73116-1423', 'city': 'Oklahoma City', 'state': 'Oklahoma', 'country': 'United States', 'facility': 'Cutting Edge Research Group /ID# 236664', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}, {'zip': '78759', 'city': 'Austin', 'state': 'Texas', 'country': 'United States', 'facility': 'BioBehavioral Research of Austin /ID# 236479', 'geoPoint': {'lat': 30.26715, 'lon': -97.74306}}, {'zip': '75251-2202', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'Cedar Health Research /ID# 259364', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '77090-2641', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Red Oak Psychiatry Associates /ID# 236602', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '75093', 'city': 'Plano', 'state': 'Texas', 'country': 'United States', 'facility': 'AIM Trials /ID# 236368', 'geoPoint': {'lat': 33.01984, 'lon': -96.69889}}, {'zip': '77381', 'city': 'The Woodlands', 'state': 'Texas', 'country': 'United States', 'facility': 'Family Psychiatry of The Woodlands /ID# 236426', 'geoPoint': {'lat': 30.15799, 'lon': -95.48938}}, {'zip': '98201', 'city': 'Everett', 'state': 'Washington', 'country': 'United States', 'facility': 'Core Clinical Research /ID# 236409', 'geoPoint': {'lat': 47.97898, 'lon': -122.20208}}, {'zip': '00727', 'city': 'Caguas', 'country': 'Puerto Rico', 'facility': 'Dr. Samuel Sanchez PSC /ID# 246047', 'geoPoint': {'lat': 18.23412, 'lon': -66.0485}}, {'zip': '00917-3104', 'city': 'San Juan', 'country': 'Puerto Rico', 'facility': 'GCM Medical Group PSC /ID# 246048', 'geoPoint': {'lat': 18.46633, 'lon': -66.10572}}], 'overallOfficials': [{'name': 'ABBVIE INC.', 'role': 'STUDY_DIRECTOR', 'affiliation': 'AbbVie'}]}, 'ipdSharingStatementModule': {'url': 'https://vivli.org/ourmember/abbvie/', 'infoTypes': ['STUDY_PROTOCOL', 'SAP'], 'timeFrame': 'For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/', 'ipdSharing': 'YES', 'description': 'AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.', 'accessCriteria': 'To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'AbbVie', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}